RxDoctor Payments Data

Odessa Hoinkis, MD

Family Medicine · Emerson, NJNPI 1255582680

Payments from drug & device makers

$721in general payments, 2019–2025

Across 13 payments — averaging $55.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$229
  • Astellas Pharma US Inc$214
  • Otsuka America Pharmaceutical, Inc.$139
  • Lilly USA, LLC$95
  • Sunovion Pharmaceuticals Inc.$30
  • Johnson & Johnson$15

What the payments were for

  • Food & beverage$53374%
  • Education$18826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 60th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$608,035
Medicare patients
610
Services billed
6,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban362$228,228
Dupixent SyringeDupilumab26$85,420
XareltoRivaroxaban81$49,620
JardianceEmpagliflozin58$37,249
JanuviaSitagliptin Phosphate50$31,359
EntrestoSacubitril/Valsartan29$19,844
RytaryCarbidopa/Levodopa17$18,509
GemtesaVibegron30$17,256
Breo ElliptaFluticasone/Vilanterol41$17,228
AbrysvoRsv Vacc, Pref A And Pref B/Pf55$16,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$16,497
Spiriva RespimatTiotropium Bromide28$16,363
Atorvastatin Calcium940$15,421
Memantine Hcl364$14,412
MyrbetriqMirabegron28$14,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$15$49,62081 claims
Astellas Pharma US IncMyrbetriq$214$14,17128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Emerson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →